Global Stem Cell Media Market 2020: Industry Analysis and Detailed Profiles of Top Key Players Thermo Fisher, STEMCELL Technologies, Merck Millipore,…

Innovate Insights unravels its new study titled Global Stem Cell Media Market Growth, Trends, and Forecast (2017-2023). Effective exploratory techniques such as qualitative and quantitative analysis have been used to discover accurate data.

The Stem Cell Media Market was estimated to be worth USD XXX billion in 2017 and is projected to reach USD XXX billion by the end of 2023, growing at a CAGR of XX% over the forecast period of 2018-2023. The Stem Cell Media industry is highly competitive, due to a large degree of fragmentation in the market. Despite the fragmentation, the market is largely tied by the regulatory requirements for establishment and operation.

The scope of the report is limited to the application of the type, and distribution channel. The regions considered in the scope of the report include North America, Europe, Asia-Pacific, and Rest of the World. This report presents the worldwide Stem Cell Media market size (value, production and consumption), splits the breakdown (data status 20142019 and forecast to 2025), by manufacturers, region, type and application.

We Have Recent Updates of Stem Cell Media Market in Sample Copy: https://www.innovateinsights.com/report/global-stem-cell-media-market-research-report-growth/76119/#requestsample

The major manufacturers covered in this report: Thermo Fisher, STEMCELL Technologies, Merck Millipore, Lonza, GE Healthcare, Miltenyi Biotec, Corning, CellGenix, Takara, PromoCell

The prime objective of this Stem Cell Media research report is to define the size of the different segments and the geographies as well as to forecast the trends that are likely to gain traction in the following couple of years.

Regional Analysis in the Stem Cell Media Market

The biggest demand for Stem Cell Media from North America, Europe, and countries, like China. Asia-Pacific is home to the worlds fastest-growing market for Stem Cell Media, which is reflected in the size of its industry and the rapid rate of expansion in output over recent years. Currently, different companies are aiming to produce Stem Cell Media in many other countries, with current and new areas and projects that are undergoing continuous exploration and feasibility tests.

Stem Cell Media Market Report to grow your business needs and!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted Price@ https://www.innovateinsights.com/report/global-stem-cell-media-market-research-report-growth/76119/#buyinginquiry

Market segment by Type, can be split into: Pluripotent Stem Cell Culture, Hematopoietic Stem Cell Culture, Mesenchymal Stem Cell Culture, Other

Market segment by Application, can be split into: Scientific Research, Industrial Production

The Stem Cell Media report highlights the most recent market trends. Stem Cell Media report unveils vulnerabilities that may emerge because of changes in business activities or presentation of another item in the market. It is designed in such a way that it provides an evident understanding of industry. This Stem Cell Media market report is generated with the combination of best industry insight, practical solutions, talent solutions and latest technology. It explains investigation of the existing scenario of the global market, which takes into account several market dynamics. Stem Cell Media report also perceives the different drivers and limitations affecting the market amid the estimate time frame.

Browse Full Report with Facts and Figures of Stem Cell Media Market Report at: https://www.innovateinsights.com/report/global-stem-cell-media-market-research-report-growth/76119/

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

See more here:
Global Stem Cell Media Market 2020: Industry Analysis and Detailed Profiles of Top Key Players Thermo Fisher, STEMCELL Technologies, Merck Millipore,...

Potential impact of coronavirus outbreak on Canine Stem Cell Therapy Market Size, Top Manufacturers, Product Types, Applications and Specification,…

Analysis Report on Canine Stem Cell Therapy Market

A report on global Canine Stem Cell Therapy market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Canine Stem Cell Therapy Market.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

Some key points of Canine Stem Cell Therapy Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Canine Stem Cell Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Canine Stem Cell Therapy Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Canine Stem Cell Therapy market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Canine Stem Cell Therapy market is analyzed and depicted in the report.

The global Canine Stem Cell Therapy market segment by manufacturers include

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

Important queries addressed in the report:

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Canine Stem Cell Therapy economic market. This included the CAGR value during the outlook period leading to 2025.

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

Benefits of Purchasing Canine Stem Cell Therapy Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

See the original post:
Potential impact of coronavirus outbreak on Canine Stem Cell Therapy Market Size, Top Manufacturers, Product Types, Applications and Specification,...

Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked…

NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) classification to MB-107, Mustangs lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease. The U.S. Food and Drug Administration (FDA) previously granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-107 for the treatment of XSCID in August 2019.

EMA grants ATMP classifications to new therapeutics that are based on genes or cells and intended as long-term or permanent therapeutic solutions to acute or chronic human diseases at a genetic, cellular or tissue level. The ATMP program provides specific regulatory guidelines for preclinical development, manufacturing and product quality testing of ATMPs and offers incentives, including fee reductions for regulatory advice, recommendations and evaluation and certification of quality and non-clinical data.

Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, We are extremely encouraged that the EMA has granted MB-107 with ATMP classification, an important step in establishing our path to market approval and commercialization in Europe. This classification complements the RMAT designation we received last year from the FDA and brings us closer to realizing our goal of commercializing MB-107 for XSCID patients, as these patients are in desperate need of innovative and potentially curative treatment options.

MB-107 is currently being assessed in two Phase 1/2 clinical trials for XSCID: the first in newly diagnosed infants under the age of two at St. Jude Childrens Research Hospital (St. Jude), UCSF Benioff Childrens Hospital in San Francisco and Seattle Childrens Hospital and the second in patients over the age of two who have received prior hematopoietic stem cell transplantation at the National Institutes of Health. Under a licensing partnership with St. Jude, Mustang intends to develop the lentiviral gene therapy for commercial use as MB-107.

About Mustang BioMustang Bio, Inc. (Mustang) is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission. Mustang was founded by Fortress Biotech, Inc. (FBIO). For more information, visit http://www.mustangbio.com.

ForwardLooking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Story continues

See more here:
Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked...

Stem Cell Therapy Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 Cole Reports – Cole of Duty

Allosource

Stem Cell Therapy Market: Competitive Landscape

The last chapter of the Stem Cell Therapy market research report focuses exclusively on the competitive landscape. It examines the main market players. In addition to a brief overview of the business, analysts provide information on their assessment and development. The list of important products in preparation is also mentioned. The competitive landscape is analyzed by understanding the companies strategies and the initiatives they have taken in recent years to overcome intense competition.

Stem Cell Therapy Market: Drivers and Restraints

The report explains the drivers of the future of the Stem Cell Therapy market. It assesses the different forces which should have a positive impact on the whole market. Analysts have looked at investments in research and development for products and technologies, which should give players a significant boost. In addition, the researchers undertook an analysis of the evolution of consumer behavior which should have an impact on the cycles of supply and demand in the Stem Cell Therapy market. In this research report, changes in per capita income, improvement in the economic situation and emerging trends were examined.

The research report also explains the potential restrictions on the Stem Cell Therapy market. The aspects assessed are likely to hamper market growth in the near future. In addition to this assessment, it offers a list of opportunities that could prove lucrative for the entire market. Analysts offer solutions to turn threats and restrictions into successful opportunities in the years to come.

Stem Cell Therapy Market: Regional Segmentation

In the following chapters, analysts have examined the regional segments of the Stem Cell Therapy market. This gives readers a deeper insight into the global market and allows for a closer look at the elements that could determine its evolution. Countless regional aspects, such as the effects of culture, environment and government policies, which affect regional markets are highlighted.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=007

What will the report contain?

Market Dynamics: The report contains important information on influencing factors, market drivers, challenges, opportunities and market trends as part of the market dynamics.

Global Market Forecast: Readers receive production and sales forecasts for the Stem Cell Therapy market, production and consumption forecasts for regional markets, production, sales and price forecasts for the Stem Cell Therapy market by type and consumption forecasts for the Stem Cell Therapy market per application.

Regional Market Analysis: It can be divided into two different sections: one for the analysis of regional production and one for the analysis of regional consumption. Here, analysts share gross margin, prices, sales, production, CAGR, and other factors that indicate the growth of all regional markets examined in the report.

Market Competition: In this section, the report provides information on the situation and trends of competition, including mergers and acquisitions and expansion, the market shares of the three or five main players and the concentration of the market. Readers could also get the production, revenue, and average price shares of manufacturers.

Key Players: The report provides company profiles for a decent number of leading players in the Stem Cell Therapy market. It shows your current and future market growth taking into account price, gross margin, income, production, service areas, production locations and other factors.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=007

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

Rich Mineral Paper Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis

Read the original post:
Stem Cell Therapy Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 Cole Reports - Cole of Duty

Coronavirus focus tipped to ‘mothball’ biotech research – The Age

Chief executive of contract research operator Novotech, Dr John Moller, said many research sites across the Asia-Pacific region were modifying operations to keep running projects remotely.

"Some sites are reconfiguring their operations to work in the new environment they may be undertaking increased levels of remote monitoring or they may move their clinical trial sites away from areas where they are likely to treat COVID patients," he said.

"A majority of sites continue to be very interested in new studies and the review and approval of non-COVID-19 clinical trials are continuing."

Despite this, company founders said the sector was facing many unknowns.

Chief executive of stem cell therapies company Cynata Therapeutics, Ross MacDonald, said recruitment for upcoming planned research was on hold as the business waited on answers.

"We don't know. We're in the same situation as everyone else at the moment, and looking to the government to ask, 'when are we getting out of this?'" he said.

Cynata's research blueprint for this year includes a phase two clinical trial of its product for treatment of osteoarthritis and critical limb ischemia, an artery disease.

Ms Chiroiu said after the pandemic was over she believed the move to remote healthcare services would be a "lasting legacy" that would enable companies to include a wider variety of Australians in research.

A move to virtual consultations could actually change how Australians recruit and monitor research patients, she said, a move policy experts have agreed would be a major win for more inclusive medical research.

Loading

"There has been lots of talk at policy level about involving more rural and remote communities in clinical trials. There's a move towards trying to conduct telehealth consults wherever possible it will be a great jump start to that," she said.

However, companies that do not have strong capital bases may not live long enough to see that change, she warned.

"Those wanting to raise money will have to wait until the other side ... and there is still investment capital around, but just much less that there was."

Follow MySmallBusiness on Twitter, Facebook and LinkedIn.

Get our Coronavirus Update newsletter for the day's crucial developments at a glance, the numbers you need to know and what our readers are saying. Sign up to The Sydney Morning Herald's newsletter here and The Age's here.

Emma is the small business reporter for The Age and Sydney Morning Herald based in Melbourne.

Read the rest here:
Coronavirus focus tipped to 'mothball' biotech research - The Age

Resilience Hope and Being a Survivor – Curetoday.com

When I first heard the word "resilience" I did not really understand what it meant, I was listening to a presentation about a third world mission trip and about how people survive their hardships there. But now, I personally understand the meaning and am ready to share my journey.

When my husband was diagnosed with cancer, I understood what may be ahead, since I am a nurse with many years of experience. The first two years of his journey were stressful, but we had each other, enjoyed our life and worked through the decisions and experience. The turning point was when he his cancer returned, and he started radiation therapy. Then, we hit what felt like a big wall.

I was diagnosed with breast cancer.

I remember sharing this news with him and he stated, "I am stronger than you think" and he proved that to be so true over the next 3 years.

Our journey together is a story of resilience, sharing hope and caring for each other. His cancer involved traveling over 3 hours to a medical center for surgery, needing an artificial airway and nutrition via a feeding tube. We spent our time together going to the local cancer center on separate days for each of our own chemotherapy treatments. As a nurse, I cared for him even during my own radiation treatment period and still kept working at my job as much as possible.

During that time, I kept thinking, is this what it takes to have that resilience? Is resilience what it takes to keep caring, maintaining hope and surviving a day at a time. If you look up the word, " resilience", there are terms like hardiness, strength and toughness. However, I have learned that it means much more.

The experience of a cancer journey together is more than what those words convey. I would often say to myself, " I am stronger than I thought too" not realizing I was beginning to understand resilience. When looking inward, you begin to understand the human spirit and what we face in life cannot truly be explained to others, but only matures every day with every hurdle we tackle and overcome.

I am a widow now and a cancer survivor, who looks back on that time in our lives, with joy of being together, with pride at how we both endured and how much stronger we became because of it. Hope was always in front of us, leading us through each day.

You should never lose hope, because that optimism is what builds the courage that leads to learning what resilience really means.

Follow this link:
Resilience Hope and Being a Survivor - Curetoday.com

What are the underlying conditions causing more serious illness from coronavirus? – KSBW The Central Coast

We've heard that elderly people and those with underlying health conditions are most at risk if they're infected with coronavirus, but those can seem like really general terms. Who does that include? And why can they face more serious illness?"According to the , some of the underlying conditions that may put you at higher risk include: chronic lung disease and asthma, heart disease and undergoing cancer treatment," said CNN Chief Medical Correspondent Dr. Sanjay Gupta. Anyone with diabetes, kidney failure or liver failure may also be at higher risk.The role of the immune system is to protect against disease or other potentially damaging pathogens. A strong one is needed to help stave off coronavirus infection."Think of it like this," Dr. Gupta suggested. "In your everyday life, you're always fighting off pathogens. Most of the time you don't even realize it. If you have an underlying condition, it makes it more challenging to fight off a virus like this. You may develop a fever, shortness of breath or a cough more easily than someone who doesn't have a preexisting illness."Additionally, there are more specific reasons why each condition has its own vulnerabilities. Here's a guide to underlying conditions affected by coronavirus and why, and how you can protect yourself or an at-risk loved one.Older adultsEight out of 10 deaths reported in the U.S. have been in adults ages 65 and older, according to the CDC. Older adults have also been more likely to require hospitalization and admission to an intensive care unit.Older adults are more likely to have long-term health problems that can increase their risk for infection and serious disease. And, our immune systems usually weaken with age, making it more difficult for people to fight off infections, according to Johns Hopkins Medicine.The quality of our lung tissue also declines over time, becoming more elastic and making respiratory diseases such as COVID-19 of important concern because of the potential for lung damage.Inflammation in older adults can be more intense, leading to organ damage.Those with lung disease, asthma or heart conditionsPeople with chronic airway and lung diseases such as chronic obstructive pulmonary disease, asthma, pulmonary fibrosis and interstitial lung disease can lay the foundations for more severe infection with coronavirus because of the inflammation, scarring and lung damage those conditions cause, Johns Hopkins Medicine reported.COVID-19 affects a person's airway and lungs, but those organs work together to provide the body with oxygen. When the lungs are overburdened with an infection, the heart has to work harder, which exacerbates the challenges of people already living with heart disease.The immunocompromisedAccording to the CDC, many conditions can cause a person to be immunocompromised, including cancer treatment, smoking, bone marrow or organ transplantation and immune deficiencies. Poorly controlled HIV or AIDS and prolonged use of man-made steroid hormones or other immune-weakening medications can also hamper a person's immune function.Cancer can weaken immunity by spreading into the bone marrow, which makes blood cells that help fight infection, according to Cancer Research UK. Cancer prevents bone marrow from making enough blood cells.Some cancer treatments can temporarily weaken the immune system, too. Because cancer treatments such as chemotherapy, cancer drugs, radiotherapy or steroids are targeted toward cancer cells, they can also diminish the number of white blood cells created in the bone marrow.A 2017 study found cigarette smoking can harm the immune system by either causing extreme immune responses to pathogens or rendering the body less effective at fighting disease. This may occur by smoking, negatively altering the cellular and molecular mechanisms responsible for keeping an immune system strong.When a person undergoes a bone marrow transplant using stem cells from a donor, or they receive an organ, a doctor may prescribe medications to prevent graft-versus-host disease and mitigate the immune system's reaction by suppressing its function. After the operation, it takes time for your immune system to be up and running again.HIV and AIDS attack the body's immune system, specifically the body's T cells, which help the immune system fight off infection. When the diseases are untreated, HIV reduces the number of those cells, making the person more likely to contract other infections or infection-related cancer, according to the CDC.Severe obesityPeople with severe obesity, or a body mass index of 40 or higher, are at higher risk of serious disease."Obesity shares with most chronic diseases the presence of an inflammatory component," a 2012 study said. Inflammatory responses were linked between the immune system and body fat. Obesity is known to impair immune function by altering white blood cell count as well as the cells that control immune responses.DiabetesPeople with type 1 or type 2 diabetes face an increased risk of getting really sick with COVID-19, as both cause a blood sugar spike. If blood sugar is poorly managed, viral diseases can be more dangerous as high blood sugar may give viruses a place to thrive, according to Diabetes in Control, a news and information resource for medical professionals.Higher levels of inflammation have been discovered in the bodies of people with diabetes, weakening the immune system and making it more difficult for those affected to stave off sickness in general.Kidney and liver diseaseThe kidneys produce several hormones that affect immune responses. Having kidney disease and failure can weaken your immune system, making it easier for infections to take hold. According to the National Kidney Foundation, doctors and researchers have found that most infections are worse in people with kidney disease.The liver is an integral member of the body's line of defense, helping to regulate the number of white blood cells utilized in immune responses and defend against harmful pathogens. Someone with liver disease is experiencing abnormalities in the function of the immune system, giving rise to more serious illness.Neurodevelopmental conditionsNeurological and neurodevelopmental conditions may also increase the risk of serious COVID-19 for people of any age.These include disorders of the brain, spinal cord, peripheral nerve and muscle such as cerebral palsy, epilepsy, stroke and intellectual disability, according to the CDC. Those with moderate to severe developmental delay, muscular dystrophy or spinal cord injury are also more at-risk.People with neurological conditions may not be more at risk due to solely their condition, but because medications they might take to control their condition could hamper their immune system. However, some neurological conditions, such as Parkinson's, have been recognized to have inflammatory components, which may harm the immune system.Others including muscular dystrophy, multiple sclerosis or amyotrophic lateral sclerosis (ALS) could cause paralysis to the diaphragm, which leaves those affected very at risk for respiratory failure if they were to be sick with COVID-19.Staying safe when you're more at riskIf you see yourself on the list of those at higher risk for severe illness, there are several things you can do to protect yourself. First, make sure you are contact your doctor or doctors about your risk level. Second, be extra vigilant about the recommendations that most people are being asked to follow.Stay home whenever possible and avoid close contact with people, the CDC suggests. Wash your hands often to prevent transferring the virus from a surface to your face, and try to clean and disinfect frequently touched surfaces as often as you can.If you don't have an underlying condition, doing your part by practicing these cautionary measures can help protect not only you, but your loved ones with existing conditions.

We've heard that elderly people and those with underlying health conditions are most at risk if they're infected with coronavirus, but those can seem like really general terms. Who does that include? And why can they face more serious illness?

"According to the [Centers for Disease Control and Prevention], some of the underlying conditions that may put you at higher risk include: chronic lung disease and asthma, heart disease and undergoing cancer treatment," said CNN Chief Medical Correspondent Dr. Sanjay Gupta. Anyone with diabetes, kidney failure or liver failure may also be at higher risk.

The role of the immune system is to protect against disease or other potentially damaging pathogens. A strong one is needed to help stave off coronavirus infection.

"Think of it like this," Dr. Gupta suggested. "In your everyday life, you're always fighting off pathogens. Most of the time you don't even realize it. If you have an underlying condition, it makes it more challenging to fight off a virus like this. You may develop a fever, shortness of breath or a cough more easily than someone who doesn't have a preexisting illness."

Additionally, there are more specific reasons why each condition has its own vulnerabilities. Here's a guide to underlying conditions affected by coronavirus and why, and how you can protect yourself or an at-risk loved one.

Eight out of 10 deaths reported in the U.S. have been in adults ages 65 and older, according to the CDC. Older adults have also been more likely to require hospitalization and admission to an intensive care unit.

Older adults are more likely to have long-term health problems that can increase their risk for infection and serious disease. And, our immune systems usually weaken with age, making it more difficult for people to fight off infections, according to Johns Hopkins Medicine.

The quality of our lung tissue also declines over time, becoming more elastic and making respiratory diseases such as COVID-19 of important concern because of the potential for lung damage.

Inflammation in older adults can be more intense, leading to organ damage.

People with chronic airway and lung diseases such as chronic obstructive pulmonary disease, asthma, pulmonary fibrosis and interstitial lung disease can lay the foundations for more severe infection with coronavirus because of the inflammation, scarring and lung damage those conditions cause, Johns Hopkins Medicine reported.

COVID-19 affects a person's airway and lungs, but those organs work together to provide the body with oxygen. When the lungs are overburdened with an infection, the heart has to work harder, which exacerbates the challenges of people already living with heart disease.

According to the CDC, many conditions can cause a person to be immunocompromised, including cancer treatment, smoking, bone marrow or organ transplantation and immune deficiencies. Poorly controlled HIV or AIDS and prolonged use of man-made steroid hormones or other immune-weakening medications can also hamper a person's immune function.

Cancer can weaken immunity by spreading into the bone marrow, which makes blood cells that help fight infection, according to Cancer Research UK. Cancer prevents bone marrow from making enough blood cells.

Some cancer treatments can temporarily weaken the immune system, too. Because cancer treatments such as chemotherapy, cancer drugs, radiotherapy or steroids are targeted toward cancer cells, they can also diminish the number of white blood cells created in the bone marrow.

A 2017 study found cigarette smoking can harm the immune system by either causing extreme immune responses to pathogens or rendering the body less effective at fighting disease. This may occur by smoking, negatively altering the cellular and molecular mechanisms responsible for keeping an immune system strong.

When a person undergoes a bone marrow transplant using stem cells from a donor, or they receive an organ, a doctor may prescribe medications to prevent graft-versus-host disease and mitigate the immune system's reaction by suppressing its function. After the operation, it takes time for your immune system to be up and running again.

HIV and AIDS attack the body's immune system, specifically the body's T cells, which help the immune system fight off infection. When the diseases are untreated, HIV reduces the number of those cells, making the person more likely to contract other infections or infection-related cancer, according to the CDC.

People with severe obesity, or a body mass index of 40 or higher, are at higher risk of serious disease.

"Obesity shares with most chronic diseases the presence of an inflammatory component," a 2012 study said. Inflammatory responses were linked between the immune system and body fat. Obesity is known to impair immune function by altering white blood cell count as well as the cells that control immune responses.

People with type 1 or type 2 diabetes face an increased risk of getting really sick with COVID-19, as both cause a blood sugar spike. If blood sugar is poorly managed, viral diseases can be more dangerous as high blood sugar may give viruses a place to thrive, according to Diabetes in Control, a news and information resource for medical professionals.

Higher levels of inflammation have been discovered in the bodies of people with diabetes, weakening the immune system and making it more difficult for those affected to stave off sickness in general.

The kidneys produce several hormones that affect immune responses. Having kidney disease and failure can weaken your immune system, making it easier for infections to take hold. According to the National Kidney Foundation, doctors and researchers have found that most infections are worse in people with kidney disease.

The liver is an integral member of the body's line of defense, helping to regulate the number of white blood cells utilized in immune responses and defend against harmful pathogens. Someone with liver disease is experiencing abnormalities in the function of the immune system, giving rise to more serious illness.

Neurological and neurodevelopmental conditions may also increase the risk of serious COVID-19 for people of any age.

These include disorders of the brain, spinal cord, peripheral nerve and muscle such as cerebral palsy, epilepsy, stroke and intellectual disability, according to the CDC. Those with moderate to severe developmental delay, muscular dystrophy or spinal cord injury are also more at-risk.

People with neurological conditions may not be more at risk due to solely their condition, but because medications they might take to control their condition could hamper their immune system. However, some neurological conditions, such as Parkinson's, have been recognized to have inflammatory components, which may harm the immune system.

Others including muscular dystrophy, multiple sclerosis or amyotrophic lateral sclerosis (ALS) could cause paralysis to the diaphragm, which leaves those affected very at risk for respiratory failure if they were to be sick with COVID-19.

If you see yourself on the list of those at higher risk for severe illness, there are several things you can do to protect yourself. First, make sure you are contact your doctor or doctors about your risk level. Second, be extra vigilant about the recommendations that most people are being asked to follow.

Stay home whenever possible and avoid close contact with people, the CDC suggests. Wash your hands often to prevent transferring the virus from a surface to your face, and try to clean and disinfect frequently touched surfaces as often as you can.

If you don't have an underlying condition, doing your part by practicing these cautionary measures can help protect not only you, but your loved ones with existing conditions.

See the original post here:
What are the underlying conditions causing more serious illness from coronavirus? - KSBW The Central Coast

Stem cells in the clinic: how are they regulated? – European Pharmaceutical Review

Dr Roger Barker, University of Cambridge, UK and Eric Anthony, International Society for Stem Cell Research (ISSCR), describe how stem cells are regulated around the world and why this is important for patient safety.

Stem cells are used to aid in the understanding and treatment of a range of diseases. According to the International Society for Stem Cell Research (ISSCR), the potential of stem cells is evident from the use of blood stem cells to treat haematological diseases. Furthermore, clinical trials involving stem cells are currently underway for many other conditions, such as diabetes and Parkinsons disease.

However, due to the relative newness of stem cells as a therapy, tight regulations are required to ensure their use poses no risk to patients and that their translation to the clinic is supported by pre-clinical data.

European Pharmaceutical Reviews Victoria Rees spoke with ISSCRs Public Policy Director, Eric Anthony and Dr Roger Barker, Professor of Clinical Neuroscience at the University of Cambridge, to discover more about the regulations regarding stem cells.

Anthony explained that in the EU, stem cells are considered advanced therapeutics, which are medicines for human use based on genes, tissues or cells. The European Medicines Agency (EMA) determines whether products fall under the advanced therapeutics category based on the level of manipulation of the product and whether it is used homologously or non-homologously. However, one notable exception to this is platelet rich plasma (PRP), which the EMA does not count as an advanced therapy.

Anthony said that the UK currently follows the rules that are adopted in the EU, which is likely to continue into next year at least. He suggested that after the UK discontinues its ties with the EU and its regulations, he expects its regulatory structure will remain similar.

The US Food and Drug Administration (FDA) also defines most stem cell products as advanced therapeutics, explained Anthony, based on minimal manipulation and homologous use. He highlighted that largely, stem cell products across the globe are defined in much the same way.

Barker explained that the key question every regulator has to ask relates to the source of the stem cells, whether in trials or in the clinic and the extent to which they have been manipulated. Other questions that regulators must answer include the consenting process behind the parent cells being used as well as determining what constitutes the final cell product. However, this latter question has proven to be quite complicated as it is often hard to know what every cell in a product is. Also, some therapies are given in an undifferentiated state with the aim of letting them differentiate and mature once grafted, which creates issues for defining the potency of the cells at the time of implantation. As stem cells will differentiate over months into the desired product, regulators need to know the correct processes are in place to ensure that this will happen in the way anticipated and that the right cells will develop out of the grafted stem cell product.

Another issue he discussed is the stability of stem cells. Once you have frozen them, how stable are they when you wake them up and transplant them at later stages?

In addition, one of the more pressing unresolved questions that Barker emphasised is the genetic variance of stem cells and their products and what this means for the safety of the cells. When researchers conduct whole genome sequencing of the stem cell products, it will convey many genetic variants but knowing what this means for the grafted cell or recipient patient is often an unknown.

Anthony explained that there are a number of consequences to giving patients unregulated stem cell treatments. The main factor is the risk posed to patients; in certain parts of the world, patients have died from stem cell therapies and others in the UK and US have been blinded, paralysed or infected by pathogens.

This, he explained, has a wider impact upon the whole field, as it can negatively impact those who have spent years developing techniques with great rationale which are then undermined by bad practice.

Companies that market unapproved stem cell therapies may not ensure their products are sourced correctly and there is also the danger of mishandling, contamination or undisclosed additives.

Barker highlighted that there is an ethical issue involved in the field of stem cells when unregulated stem cell products are used, it can exploit desperate patients. Therefore, regulations need to ensure patients stay safe and that the industry remains ethical, but not restrict pharma to the extent that it prevents any progress in the field.

A regulator cannot decide what a product is without actually examining the product, said Anthony, explaining this is one of the problems that regulators face. As regulators need to determine the safety and proper sourcing of stem cells physically, they are restricted by both time and financial constraints.

He also highlighted that the current regulations for stem cells mean some companies market their products as PRP, which are regulated as blood products, so are not treated in the same way as advanced therapies. However, these claims are not validated, making them unsubstantiated. As the EMA does not regulate PRP as an advanced therapy product, these companies exploit a loophole in regulation.

Despite this, Anthony does not believe there is a big hole in regulations that is allowing these companies to sell their products.

Instead, he argued that the wider issue for regulators is that these companies exist but the resources to properly inspect facilities and enforce regulations can be problematic. For example, there are up to 70 clinics in the UK, but there needs to be a substantial increase in the number of inspections, according to Anthony.

To improve the regulation of stem cells there needs to be more harmonisation across the globe, said Barker. If regulations across countries and continents could relate to one another, this would enable more consistency and clarity for companies and researchers. Issuing statements, documents and guidelines that anyone can use would be the ideal way to improve the industry, remarked Barker, especially as the definitions are already similar. This could also lead to an effective network for those in the field to connect to the relevant advisors.

Anthony concurred, arguing that there are providers and physicians who could use a better education about how certain products are regulated. For example, he explained, the UK and each EU member state decides its own hospital exemptions for stem cells however, in this regard, there could be better education for physicians about what is classified as an advanced therapy.

Both Barker and Anthony agree that the future of stem cell therapies requires collaboration, such as the synchronised education of clinicians, scientists and regulators. Enabling these groups to work together and earlier would streamline the process and ensure that products are safe and efficacious before going to market.

Read more here:
Stem cells in the clinic: how are they regulated? - European Pharmaceutical Review

NHS’s oldest IVF clinic at risk of closure amid increasing privatisations – The Guardian

The UKs oldest NHS fertility clinic is at risk of closure and another has been put out to private tender, as IVF provision is increasingly privatised and rationed.

Hospital bosses want to close the internationally renowned department of reproductive medicine at St Marys hospital, Manchester, saying they cannot afford to fund a 10m upgrade of the unit, the Guardian has learned.

In Leeds, the entire NHS provision of fertility and other gynaecology services was put out to tender earlier this year, with private clinics invited to bid for a 10-year contract estimated at 70m to provide reproductive care.

Two years ago North Bristol NHS trust sold off its IVF clinic to a private provider, saying it was no longer feasible because of a reduction in NHS-funded patients.

In England, the proportion of fertility treatment funded by the NHS dropped from 39% in 2012 to 35% in 2017, according to figures published last year by the regulator, the Human Fertilisation and Embryology Authority (HFEA). This is at odds with the rest of the UK, where public funding has remained stable or increased.

When it opened in 1982, four years after the first test tube baby, Louise Brown, was born in nearby Oldham, St Marys was the UKs first fully NHS funded IVF unit. It now performs over 2,000 fertility treatments every year, including around 1,200 IVF cycles, and offers highly specialised fertility preservation for cancer patients. It is also a top research centre, which led on the use of ovarian reserve tests to guide ovarian stimulation, the development of stem cell lines from human embryos, and the effects of IVF on baby birth weights.

The Manchester University NHS foundation trust (MFT) said no decisions had been made over the units future. But staff were briefed last month that the HFEA and local clinical commissioning groups (CCGs) had been told that all licensed treatment and research on the site may end by April 2021 if an alternative solution cannot be found.

MFT, which runs the hospital, is also exploring options including redeploying services and some of its 107 staff including many highly specialised roles but confirmed to staff that closure was a possibility.

The Guardian spoke to 10 members of staff at St Marys aware of the mooted closure. One said they understood the matter to be settled: St Marys have taken a proposal to the MFT group board to discontinue the IVF service and the group board have said, Yes, OK. How they discontinue it is what they need to decide next, they said.

If the change goes ahead, CCGs, which fund fertility treatment, will have to pay private clinics to carry out IVF and other fertility services. But staff at St Marys warn that the private sector will not be able to carry out some of the most specialised services currently offered by the NHS.

We offer highly specialised procedures in the NHS which private providers wont touch because they dont make money and are too difficult. For example, we aim to see women diagnosed with cancer within a week who want to freeze their eggs before they start chemotherapy. Many of these women are already very poorly and need really high quality anaesthetic care during egg collection, and that is just not available in the private sector because of the medical complications, said one source.

They added: Private clinics are also unlikely to help patients with kidney problems or heart problems. But when they come to us, we can address these issues before they begin IVF: a huge advantage of being part of a multi-disciplinary NHS Trust. Those patients will be disadvantaged if this happens.

They also expressed concerns about screening procedures in the private sector. In the NHS, anyone applying for fertility treatment undergoes a series of stringent checks, including an assessment of the welfare of the child: Our checks and ethics advisory committee often flag issues including prison sentences, a serious history of domestic violence, even people on the sex offender register. At private clinics they dont do anything like the same background checks.

A number of separate proposals were put to MFT to try to save some or all of the clinic, including turning the service into a social enterprise and forming a partnership with a private provider, as is being proposed in Leeds.

The deadline to apply to run the Leeds service was 23 March, the day the government announced the coronavirus lockdown in the UK. Shortly afterwards, clinics stopped all new treatments and the HFEA ordered private and NHS clinics to stop treating patients in the middle of an IVF cycle by 15 April.

A spokesperson for the MFT, which runs St Marys hospital, said no decision had been taken to shut the clinic permanently.

They said: Services provided by the department of reproductive medicine at St Marys hospital are regularly reviewed as part of a usual cycle to ensure that we continue to provide the best possible care and treatments for all our service users. No decisions have been made, therefore it would be inappropriate to provide any further detail before the outcome of any review has been finalised.

The HFEA said it could not disclose informal discussions between clinics and inspectors.

Many St Marys staff are worried not just about their patients and their jobs, but the logistics of closing down the clinic. Moving thousands of sperm samples and embryos held in freezers, for use in both treatment and research, was a mind-boggling challenge, said one.

One staff member said: Although possible relocation was mentioned, the fact that no viable alternative has been identified and that the cost was described as being too high left us thinking that this is not being explored and that closing the unit is the direction of travel. We are worried for our jobs but our biggest concern is for our patients, particularly those with the most complex needs who cannot be served elsewhere without high costs.

IVF provision has been put under pressure, nationally, by NHS funding cuts over the past decade leading to a postcode lottery of provision. Now only a minority of English CCGs offer the recommended three funded IVF cycles, with some refusing to fund any NHS fertility treatment at all.

Read this article:
NHS's oldest IVF clinic at risk of closure amid increasing privatisations - The Guardian

Stem cell activity linked to lifestyle – Harvard Magazine

Sleep, diet, exercise, and stress: these are factors known to change a persons risk of developing numerous non-communicable diseases. Such lifestyle impacts on healthbeneficial or harmfulexert much of their influence via inflammation. About 10 years ago, Matthias Nahrendorf began wondering just how inflammation and lifestyle might be linked biologically, and started thinking about how to pinpoint the mechanism in the cardinal case of cardiovascular disease.

A persons level of inflammation can easily be measured with a simple white blood cell test. White blood cells fight off bacterial invasions and repair damaged tissues, but they can also damage healthy tissue when they become too abundant. You can find them in atherosclerotic plaques, and you can find them in acute infarcts, says Nahrendorf, a professor of radiology who conducts high-resolution imaging research at Massachusetts General Hospital. You can find them in failing hearts and the brain, where they increase the risk of stroke.

By linking exercise to reduced white blood cell production, Nahrendorf shows how a lifestyle factor can modulate cardiovascular risk.

When Nahrendorf learned that the most potent, toxic, and pro-inflammatory white blood cells live only a few hours, or at most a day, he immediately realized that the paramount questionsgiven that they die off quickly yet remain abundant in the bloodare, where and why are they produced? What is their source? Perhaps, he hypothesized, lifestyle factors regulate hematopoiesis (blood production).

To test this idea, he decided to study the effects of exercise on the production of these leukocytes in healthy mice. First, though, he consulted the scientific literature on exercise in mice. Previous researchers, he learned, had found that exercise increases production of inflammatory immune cellswhich I thought was counterintuitive, Nahrendorf recalls. When he looked more carefully, he discovered that the type of exercise used in the studies was forced and thus possibly stressful because it was induced by electric shocks. He therefore decided to test only voluntary exercise. He and his colleagues put a wheel in each mouses cage, so the animals could choose to run if they were interested.

The mice never ran during the day. That is when they rest, Nahrendorf explains. But in the dark, they ran a lot, averaging six to seven miles every night. After three weeks, the exercising mice had measurably lower levels of circulating white blood cells. Exercise, he found, had pushed their blood stem cells (cells that can produce all the different types of blood cells) into a state of quiescence: a kind of dormancy in which they generate fewer pro-inflammatory white blood cells and platelets, without decreasing the number of oxygen-carrying red blood cells. Soon the exercising mice had fewer circulating white blood cells than their sedentary counterparts, dampening inflammationan effect that persisted for weeks.

The local signals within bone marrow that induce quiescence in blood stem cells were already well known, but the fact that exercise could trigger them was not. Nahrendorf next wanted to learn the identity of the trigger linking exercise to blood stem cell quiescence. Further investigation revealed that the only receptors with enhanced activity in the bone marrow niche where most blood stem cells exist were binding to a well-known hormone called leptin; it is produced by fat cells and regulates hunger.

Leptin is like the fuel gauge in a car. When the tank is fullmeaning energy (and food) are abundantleptin levels run high. As exercise uses up the gas in the tank, this lowers leptin levels, which signal that reserves are running low, thereby inducing hunger and the urge to eat in order to replenish depleted energy stores. Nahrendorf and his co-authors speculate in their 2019 Nature Medicine paper that leptins role in regulating energetically costly hematopoiesis may have evolved to produce blood cells only when whole body energy was abundantnot when people are exerting themselves. Contemporary sedentary behavior, they continue, which increases leptin and consequently hematopoiesis, may have rendered this adaptation a risk factor for cardiovascular disease (CVD) and perhaps also for other diseases with inflammatory components.

But with fewer circulating immune cells, would exercising mice be more vulnerable to infection? Nahrendorf challenged them with a protocol designed to induce infection in the blood, and found just the opposite: exercising mice had a more robust immune response, as semi-dormant blood stem cells swiftly sprang into activity and produced infection-fighting leukocytes, improving survival of the active mice as compared to those with no running wheels in their cages. Next, they investigated whether exercise would help mice with established atherosclerosis, and found that exercise was not only protective, it also reduced the size of existing plaques in the aorta.

Whether these associations would hold up in humans remained an open question. For answers, Nahrendorf turned to a study known as CANTOS, which had measured levels of inflammation in 4,892 patients who suffered heart attacks (see Raw and Red Hot, May-June 2019, page 46). When he approached the studys co-authors, Mallinckrodt professor of medicine Peter Libby and Braunwald professor of medicine Paul Ridker, he learned, serendipitously, not only that they possessed self-reported exercise levels for the participants, but also that they had tested leptin levels as well. They analyzed their raw data and found the same relationship among exercise, leptin, and leukocytes as in the mice. Data from a second human study cemented the result.

By identifying a previously unknown molecular mechanism linking voluntary exercise to reduced white blood cell production, Nahrendorf and his colleagues have highlighted how a lifestyle factor can modulate cardiovascular risk. Their discovery, the researchers hope, will point the way to wider adoption of healthy exercise regimens, and health-enhancing anti-inflammatory drugs.

Go here to see the original:
Stem cell activity linked to lifestyle - Harvard Magazine